Eli Lilly and biotechnology company HAYA Therapeutics have announced a multi-year agreement to apply HAYA’s RNA-guided regulatory genome platform to support preclinical drug discovery efforts in obesity and related metabolic conditions. The partners aim to identify multiple regulatory genome derived RNA-based drug targets to address these chronic conditions. Under the… Read More
Scale Biosciences (Scale Bio) has launched the ‘100 Million Cell Challenge’, which hopes to push the boundaries of single-cell genomics research, in collaboration with Ultima Genomics and NVIDIA. The programme calls on researchers worldwide to submit proposals for large-scale single cell projects, with the goal of… Read More
DDW's Diana Spencer caught up with Dr Patrick Short, CEO and Co-Founder, Sano Genetics, about the challenges facing personalised medicine development and his own personal experience of genetic conditions. DS: You and your co-founders met at the University of Cambridge. Can you tell us about the founding of the company?… Read More
A new study has provided the most comprehensive analysis to date of the genetic makeup of colorectal cancer (CRC), providing unique understanding of its response to treatment. The research was led by UK universities, including the University of Oxford, The Institute of Cancer Research, London, the… Read More
This is the latest episode of the free DDW narrated podcast, titled “Innovation drivers and opportunities for drug discovery”, which covers three articles written Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: Optimising AAV capsid purification through improved analytics How… Read More
UK researchers have mapped the exact variants in a gene that dramatically increase a person’s risk of developing cancer, paving the way for targeted treatment across diverse populations. Over 5,000 genetic variants that enable certain cancers to thrive were identified, along with a potential therapeutic target… Read More
Dr Daniel Turner, Chief Scientific Officer, Enhanc3D Genomics, outlines how 3D genomics offers a radically novel approach to address challenges in drug target discovery and how it can affect change in drug target identification, cell therapy and personalised medicine. 3D genome folding DNA within the cell nucleus is more than… Read More
Dr Gloria Gonzalez-Aseguinolaza, Co-Founder & Chief Scientific Officer of Vivet Therapeutics, has been awarded the Rosalind Franklin Society (RFS) Special Award in Science given by Mary Ann Liebert, Inc. and the Rosalind Franklin Society. The award recognises Dr Gonzalez-Aseguinolaza’s remarkable contributions and dedication to advancing scientific… Read More
A global collaboration led by scientists at the University of Oxford has discovered that genetic variants in a specific gene cause a rare neurodevelopmental disorder (NDD). NDD is a collective term for severe impairments in how the brain functions that impact learning, behaviour, speech, and movement. Read More
Researchers at the Francis Crick Institute have mapped all the possible outcomes of changes to a tumour-suppressing gene called VHL. The VHL map could help clinicians work out which patients are at risk of developing kidney cancer or might respond to certain drugs. It… Read More
The latest episode of the DDW Highlights podcast and vodcast is now available to listen to or watch below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. The last few days have seen some interesting developments… Read More
News round-up for 1-5 July by DDW Senior Digital Content Editor Diana Spencer. The last few days have seen some interesting developments related to gene editing, including the discovery of a new mechanism for genetic programming and evidence in favour of redosing CRISPR-based therapies, as well as significant… Read More
Intellia Therapeutics has shared the first-ever clinical data demonstrating the potential for redosing with an investigational in vivo CRISPR-based therapy. The data from the ongoing Phase I study of NTLA-2001, a single-dose treatment in development for transthyretin (ATTR) amyloidosis, were presented at the Peripheral Nerve Society Annual Meeting. Read More
The findings from a single-patient gene therapy trial in Canada show promise in halting the progression of spastic paraplegia type 50 (SPG50). SPG50 is an ultra-rare progressive neurodegenerative disorder that causes developmental delays, speech impairment, seizures, progressive paralysis of all four limbs, and is typically fatal… Read More
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Janssen-Cilag’s Balversa (erdafitinib). It is recommended as a monotherapy to treat adult patients with unresectable or metastatic urothelial carcinoma, harbouring susceptible FGFR3 genetic alterations who have previously received at… Read More
The DDW Summer issue is out now and looks at where the global biotech hubs are for drug discovery and development, asks how 3D genomics can accelerate personalised medicine, and looks at the technological advances in mass spectrometry. It also includes an exclusive global cancer research guide examining the innovation happening… Read More
